PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma

Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2216-2217. doi: 10.1007/s00259-019-04636-6. Epub 2020 Jan 11.

Authors

L M Mittlmeier^{1

2}, M Unterrainer^{2

3}, A Todica², C C Cyran³, S Rodler¹, P Bartenstein², C G Stief¹, H Ilhan², M Staehler⁴

Affiliations

¹ Department of Urology, University Hospital, LMU Munich, Munich, Germany.
² Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
³ Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
⁴ Department of Urology, University Hospital, LMU Munich, Munich, Germany. michael.staehler@med.uni-muenchen.de.

PMID: 31925458
DOI: 10.1007/s00259-019-04636-6

No abstract available

MeSH terms

Carcinoma, Renal Cell* / diagnostic imaging
Carcinoma, Renal Cell* / drug therapy
Edetic Acid
Glutamate Carboxypeptidase II
Humans
Kidney Neoplasms* / diagnostic imaging
Kidney Neoplasms* / drug therapy
Male
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms*
Tyrosine

Substances

Tyrosine
Edetic Acid
Glutamate Carboxypeptidase II